N-Acetyl Semax Amidate
Research chemical · Grade C
Goals
cognition
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
The resulting compound has an estimated half-life of 4-6 hours — a massive pharmacokinetic advantage over Semax's 3-5 minutes — without altering the core sequence that interacts…
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.